| 12.76 0.25 (2%) | 05-08 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 17.74 |
1-year : | 20.22 |
| Resists | First : | 15.19 |
Second : | 17.31 |
| Pivot price | 14.02  |
|||
| Supports | First : | 11.75 |
Second : | 9.77 |
| MAs | MA(5) : | 12.85 |
MA(20) : | 14.44 |
| MA(100) : | 10.29 |
MA(250) : | 6.94 |
|
| MACD | MACD : | 0 |
Signal : | 0.4 |
| %K %D | K(14,3) : | 17.7 |
D(3) : | 19.7 |
| RSI | RSI(14): 45.2 |
|||
| 52-week | High : | 17.31 | Low : | 2.67 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ RLAY ] has closed above bottom band by 29.4%. Bollinger Bands are 119.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 25 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 12.88 - 12.95 | 12.95 - 13.03 |
| Low: | 12.23 - 12.32 | 12.32 - 12.41 |
| Close: | 12.62 - 12.75 | 12.75 - 12.88 |
Relay Therapeutics, Inc. operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company's lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and RLY-1971, an oral small molecule inhibitor of protein tyrosine phosphatase Src homology region 2 domain-containing phosphatase-2 that is in Phase 1 trial in patients with advanced solid tumors. It has collaboration and license agreements with D. E. Shaw Research, LLC to research certain biological targets through the use of D. E. Shaw Research computational modeling capabilities focused on analysis of protein motion to develop and commercialize compounds and products directed to such targets; and Genentech, Inc. for the development and commercialization of RLY-1971. The company was formerly known as Allostery, Inc. and changed its name to Relay Therapeutics, Inc. in December 2015. Relay Therapeutics, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Fri, 08 May 2026
Relay Therapeutics, Inc. (NASDAQ:RLAY) Analysts Are Cutting Their Estimates: Here's What You Need To Know - Yahoo Finance
Thu, 07 May 2026
Relay Therapeutics (RLAY) Q1 Loss Of US$73.3 Million Tests Growth At A Loss Narrative - Sahm
Wed, 06 May 2026
Relay Therapeutics Q1 2026 earnings preview - MSN
Tue, 05 May 2026
Relay Therapeutics, Inc. (RLAY) reports Q1 loss, lags revenue estimates - MSN
Tue, 05 May 2026
Relay Therapeutics Reports First Quarter 2026 Financial Results and Corporate Updates - Investing News Network
Tue, 05 May 2026
Relay breast cancer drug gets FDA breakthrough, Phase 3 next - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 191 (M) |
| Shares Float | 107 (M) |
| Held by Insiders | 1.5 (%) |
| Held by Institutions | 91.4 (%) |
| Shares Short | 27,000 (K) |
| Shares Short P.Month | 19,850 (K) |
| EPS | -1.62 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.25 |
| Profit Margin | 0 % |
| Operating Margin | -899 % |
| Return on Assets (ttm) | -25.4 % |
| Return on Equity (ttm) | -41.2 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.28 |
| Sales Per Share | 0.08 |
| EBITDA (p.s.) | -1.57 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -235 (M) |
| Levered Free Cash Flow | -143 (M) |
| PE Ratio | -7.93 |
| PEG Ratio | 0 |
| Price to Book value | 3.91 |
| Price to Sales | 158.95 |
| Price to Cash Flow | -10.37 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|